centromere proteins A
Systemic Sclerosis
Systemic sclerosis (SSc) is a chronic, multisystem, heterogeneous autoimmune disease. Individuals with SSc have a mortality rate approximately 2.8 times that of the general population. In the United States, the incidence is approximately 15 cases per 100,000 person-years.
The disease is characterized by inflammation, vasculopathy, and progressive fibrosis of the skin and internal organs.
SSc is frequently referred to as scleroderma; however, scleroderma includes SSc and localized forms of scleroderma that affect only the skin.
The 2 main types of SSc are defined according to the pattern of skin involvement:
limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc).
In lcSSc, skin thickening is present distal to the elbows and knees, and facial skin thickening may or may not be present.
In contrast, dcSSc is characterized by thickening of the skin of the whole extremity, as well as that of the anterior chest, abdomen, and back, with or without facial skin involvement.
Multiple organs, including the heart, lungs, gastrointestinal tract, and kidneys, can be affected in both forms, though organ involvement is generally less severe in lcSSc.
CREST syndrome (calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia) occurs frequently in lcSSC but can also occur in longstanding dcSSc.
Of patients with SSc, approximately 55% have lcSSc and 35% have dcSSc. The remaining 10% of patients with SSc have sine scleroderma or an overlap syndrome.
Sine scleroderma is a form of SSc that has characteristic clinical features but spares the skin. Overlap syndromes occur when features of another autoimmune disease are present along with SSc.
Early treatment of SSc can improve outcomes, so prompt diagnosis is important. However, diagnosis can be challenging because many patients present with nonspecific symptoms such as Raynaud phenomenon, gastroesophageal reflux, puffy fingers, and fatigue.
In addition, patients with other autoimmune disorders may present with symptoms suggestive of SSc. Testing for autoantibodies that are associated with SSc assists diagnosis and can help predict organ involvement and severity of disease.
References:
Lee YH. Overall and sex- and disease subtype-specific mortality in patients with systemic sclerosis: an updated meta-analysis. Z Rheumatol. 2019;78(2):195-201. doi:10.1007/s00393-018-0492-8
Fan Y, Bender S, Shi W, et al. Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States. J Manag Care Spec Pharm. 2020;26(12):1539-1547. doi:10.18553/jmcp.2020.20136
Lee JJ, Pope JE. Diagnosis and management of systemic sclerosis: a practical approach. Drugs. 2016;76(2):203-213. doi:10.1007/s40265-015-0491-x
Young A, Khanna D. Systemic sclerosis: commonly asked questions by rheumatologists. J Clin Rheumatol. 2015;21(3):149-155. doi:10.1097/RHU.0000000000000232
Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-1699. doi:10.1016/s0140-6736(17)30933-9
Biomarkers in this category
14 biomarkers · optimal ranges shown
An autoantibody associated with limited cutaneous systemic sclerosis (CREST).
found in about 4% to 10% of patients with SSc
present in 2% to 11% of SSc patients
present in 2% to 11% of SSc patients
RNA polymerase epitopes 11
RNA polymerase epitopes 155
aka Topoisomerase I Antibody
aka Topoisomerase I Antibody
What Is the SCL-70 Antibody Test? The SCL-70 antibody test is a blood test used to detect antibodies against topoisomerase I, an enzyme found in the nucleus of cells. These antibodies are part of the antinuclear antibody (ANA) family and are often associated with certain autoimmune conditions—most notably systemic sclerosis (scleroderma). This test helps doctors evaluate symptoms such as skin thickening, joint pain, fatigue, or shortness of breath that may be related to autoimmune diseases. Reference Range: < 1.0 AI (Antibody Index) — Negative <1.0 AI: Negative (normal) 1.0–1.5 AI: Borderline >1.5 AI: Positive (elevated antibody levels) AI (Antibody Index) is a standardized unit that reflects the strength or concentration of antibodies in the blood. What Does a Positive or Elevated SCL-70 Antibody Mean? A positive SCL-70 antibody result (AI ≥ 1.0) may indicate an autoimmune response, particularly: Systemic sclerosis (diffuse scleroderma) – a chronic autoimmune disease that causes hardening and tightening of the skin and can affect internal organs like the lungs and kidneys. The presence of SCL-70 antibodies is most strongly linked to the diffuse cutaneous form of scleroderma and may correlate with lung involvement (pulmonary fibrosis). However, a positive result does not confirm a diagnosis on its own. It must be interpreted alongside clinical symptoms, physical examination, and other tests (like ANA, anti-centromere antibodies, and imaging). What Does a Negative SCL-70 Antibody Result Mean? A result below 1.0 AI is considered negative, suggesting that SCL-70 antibodies were not detected in the blood. This lowers the likelihood of systemic sclerosis but does not completely rule out autoimmune disease, as other antibodies may be involved. When Is This Test Ordered? Your healthcare provider may order the SCL-70 antibody test if you’re experiencing symptoms such as: Thickened or tight skin Raynaud’s phenomenon (fingers turning white or blue in cold) Joint or muscle pain Shortness of breath or signs of lung involvement Fatigue or gastrointestinal symptoms In summary, the SCL-70 antibody test is a valuable tool in diagnosing and monitoring systemic sclerosis, especially its diffuse form. A positive result warrants further evaluation by a rheumatologist to determine the underlying cause and appropriate treatment.
found in 2% to 5% of SSc patients
found in 2% to 14% of SSc patients
found in 2% to 14% of SSc patients
found in 2% to 14% of SSc patients